Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q3 2023 Earnings Call Transcript

Adrian Rawcliffe: So I’m not going to give specific time lines, but the only thing I am going to do is say that we will likely be in a position to disclose the interim data analysis. Once we have completed enrollment of all of the patients in that study. As previously stated we do – we do intend for this study to be registrational and we do not want to introduce any bias into the – into the patient enrolment and so that will be the earliest point as when we give interim analysis in interim data sets.

Peter Lawson: Perfect. Thank you so much. And then on the premium, I apologize if I missed this, but there are the components you’re going to be engineering into the T cell, whether it’s CD8 or if you use in the TCR square approach?

Adrian Rawcliffe: Jo, do you want to talk about how we think about that?

Jo Brewer: So we’re really thinking about doing those as individual kind of test products. So we’re looking at the merits of each of those next gens individually to see how well those will perform.

Peter Lawson: Okay. So you kind of be almost like a big option of those various components of the CDA.

Jo Brewer: Yes. Yes.

Adrian Rawcliffe: And I think, Jo, you commented earlier that it might be that in different settings, different next-generation approaches are more or less useful. So we’ll be taking that into account as well.

Jo Brewer: Yes.

Peter Lawson: Okay. Thanks so much.

Adrian Rawcliffe: Thanks you. Thanks Peter.

Operator: Thank you. And we have a second line from Peter Lawson from Barclays. So please go ahead.

Adrian Rawcliffe: Peter, you have other questions? Okay?

Operator: So I think that was a duplicate.

Adrian Rawcliffe: So I think that was a repeat, operator.

Operator: Yes, exactly. Thank you. So we have no further questions registered at this time. I would now like to turn the meeting back over to you, Mr. Rawcliffe.

Adrian Rawcliffe: Thanks very much. And thanks, everybody, for your time today and the questions across the breadth of the portfolio we now are developing. I am looking forward to updating you on the three key things in the course of the coming months.

.: In the meantime, if you have any questions, please do reach out. Thanks for your time today. Take care.

Operator: Thank you. The conference has now ended. Please disconnect your lines at this time, and we thank you for your participation.